No in­tro­duc­tions nec­es­sary: A TCR up­start with deep-pock­et back­ers part­ners with one of the new play­ers in the hot ...

3 years ago
Deals

Amid a fast launch, ten23 is look­ing to fur­ther ex­pand its man­u­fac­tur­ing out­put in Switzer­land

3 years ago
Manufacturing

Long-time health­care in­vestor looks to dou­ble num­ber of life sci­ences star­tups in its 'ev­er­green' fund

3 years ago
Financing

Mor­phoSys out-li­cens­es two an­ti­bod­ies to se­cre­tive ARCH biotech as it push­es for­ward with lead Con­stel­la­tion work

3 years ago
Deals

Pfiz­er's Paxlovid does­n't stack up as well for those who are vac­ci­nat­ed, new da­ta show

3 years ago
Coronavirus

Third Rock push­es newest fund over $1B line as it marks 15 years in ven­ture cap­i­tal

3 years ago
Financing

95% of new on­col­o­gy drugs ap­proved in US be­fore Eu­rope in past decade, study finds

3 years ago
R&D

Brook­ings is­sues rec­om­men­da­tions for gener­ic drug com­pe­ti­tion as PDU­FA VI ex­pi­ra­tion looms

3 years ago
Pharma

FDA warns Span­ish drug and API man­u­fac­tur­er over mul­ti­ple pro­duc­tion line prob­lems

3 years ago
FDA+
Manufacturing

While a small sam­pling, BIO's third di­ver­si­ty re­port pro­vides 'bench­mark' for da­ta-fo­cused in­dus­try to fur­ther ...

3 years ago
People

Cannes Li­ons 2022: Phar­ma and health cre­atives ea­ger to re­turn in per­son, ready to min­gle with main­stream ad crowd

3 years ago
Pharma
Marketing

Mar­ket­ingRx roundup: Pfiz­er keeps spot­light on JAKs with Cib­in­qo TV ad; Dex­com amps di­a­betes aware­ness in UK ef­fort

3 years ago
Pharma
Marketing

Boston start­up looks to make a big man­u­fac­tur­ing push with new fund­ing round

3 years ago
Financing
Startups

Covid-19 roundup: Eu­ro­pean gov­ern­ments push to rene­go­ti­ate vac­cine con­tracts — re­port; As PhII da­ta dis­ap­point, ...

3 years ago
Coronavirus

Lil­ly's Olu­mi­ant gets new FDA ap­proval, nab­bing a land­mark green­light for au­toim­mune hair loss dis­ease

3 years ago
Pharma
FDA+

In draft re­port, ICER says Amy­lyx's ALS drug would not be cost ef­fec­tive if priced sim­i­lar­ly to old­er treat­ment

3 years ago
R&D
Pharma

Fol­low­ing bis­pe­cif­ic deal with Pfiz­er, qui­et Cal­i­for­nia biotech rais­es $65M, heads to the clin­ic

3 years ago
Financing

Bavar­i­an Nordic seals Eu­ro­pean sup­ply deal for small­pox/mon­key­pox vac­cine

3 years ago
Pharma

Ameet Mallik taps fel­low No­var­tis alum to lead busi­ness de­vel­op­ment at ADC Ther­a­peu­tics

3 years ago
People

In­ter­view with the Broad In­sti­tute's David Liu: Is this the year base edit­ing makes its mark?

3 years ago
Cell/Gene Tx

Up­dat­ed: Al­ny­lam scores OK for sec­ond-gen hAT­TR ther­a­py as the space heats up

3 years ago
Pharma
FDA+

Ger­man man­u­fac­tur­er hit with Form 483 for mul­ti­ple pro­duc­tion is­sues

3 years ago
FDA+
Manufacturing

Organon inks $103M deal for per­tuzum­ab and deno­sum­ab biosim­i­lars

3 years ago
Deals
Pharma

CBER to in­dus­try: Nor­mal op­er­a­tions will re­sume in 2023

3 years ago
FDA+
First page Previous page 513514515516517518519 Next page Last page
A service from the Financial Times